PULMATRIX, INC. Purchase Obligation, to be Paid, Year Four
PULMATRIX, INC. (PULM) had Purchase Obligation, to be Paid, Year Four of $1.40 million as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInFourthYear · last filed 2023-11-09
- 2023-09-30: Purchase Obligation, to be Paid, Year Four $1.40M.
| Period end | Purchase Obligation, to be Paid, Year Four |
|---|---|
| 2023-09-30 | $1.40M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |